GobioLab Applies to US FDA for Clinical Trials of Microbiome New Drug
[Asia Economy Reporter Minwoo Lee] Gobiolab announced on the 4th that it has submitted an application for a Phase 2a clinical trial plan for its microbiome drug KBL697 to the U.S. Food and Drug Administration (FDA).
This Phase 2a clinical trial will be conducted in Australia, targeting patients with mild to moderate ulcerative colitis. After pre-treatment with vancomycin, KBL697 will be administered, and its efficacy and safety will be evaluated to confirm the therapeutic effect.
Hot Picks Today
While Samsung Falters, China Rises: "Chinese DRAM" Turns a Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
The company stated, "KBL697 demonstrated safety and tolerability in the Phase 1 trial with no clinically significant adverse reactions, suggesting it can be developed as an ulcerative colitis treatment with low toxicity and side effects."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
